Fenretinide has shown positive results for slowing the progression of dry macular degeneration in its Phase II trial. Sirion Therapeutics announced the positive results after all patients participating in the trial had reached their 12 month visit.
Fenretinide is an oral vitamin A binding protein that has been used in patients with advanced dry macular degeneration. It is believed that the accumulation of retinol or vitamin A toxins can be halted by Fenretinide, thus slowing the formation and accumulation of toxic by-products typically associated with dry macular degeneration.
Patients in the Phase II trial were either treated with a placebo or fenretinide. Patients treated with 300 mg of oral fenretinide showed slower growth and slower progression of their dry macular degeneration, 22.7 percent versus 41.6 percent in the placebo growth.
Based on the results, Sirion plans to continue its study to its conclusion and will meet with its scientific advisors and FDA to design an an appropriate Phase III trial for fenretinide.
With the results of Fenretinide at slowing the progression of dry macular degeneration, this may offer hopes to those patients diagnosed with the eye disease. Currently, there are few treatment options for dry macular degeneration.